Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB; PLUR=YES; OP=ADJ		
L2	(encephalitis) same (viral or virus$) same(alpha4 or 'vla-4')	2	L2
L1	(encephalitis) same (viral or virus$) and (alpha4 or 'vla-4')	41	L1

END OF SEARCH HISTORY

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
ENCEPHALITIS.USPT,PGPB.	3762
ENCEPHALITI.USPT,PGPB.	1
VIRAL.USPT,PGPB.	47119
VIRALS.USPT,PGPB.	337
ALPHA4.USPT,PGPB.	148
ALPHA4S	0
VLA-4.USPT,PGPB.	599
VLA-4S	0
VIRUS$	0
VIRUS.USPT,PGPB.	53937
VIRUSABILITY.USPT,PGPB.	2
((ENCEPHALITIS) SAME (VIRAL OR VIRUS$) SAME(ALPHA4 OR 'VLA-4')).USPT,PGPB.	2

There are more results than shown above. Click here to view the entire set.

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L2

Refine Search

Recall Text | Clear

Search History

DATE: Friday, March 07, 2003 Printable Copy Create Case

WEST

End of Result Set

☐ Generate Collection Print

L2: Entry 2 of 2 File: USPT Nov 19, 2002

US-PAT-NO: 6482849
DOCUMENT-IDENTIFIER: US 6482849 B1

TITLE: Inhibitors of .alpha.4.beta.1 mediated cell adhesion

DATE-ISSUED: November 19, 2002

US-CL-CURRENT: 514/430; 514/355, 514/400, 514/419, 514/448, 514/471, 514/478, 514/562, 514/563, 514/566, 546/316, 548/338.1, 548/495, 549/493, 549/69, 560/13, 560/27, 560/41, 562/430, 562/432

APPL-NO: 09/ 102584 [PALM]
DATE FILED: June 23, 1998

PARENT-CASE:
This application claims priority on provisional application Serial No. 60/050,515 filed on Jun. 23, 1997, the entire contents of which are hereby incorporated by reference.

WEST

End of Result Set

☐ Generate Collection Print

L2: Entry 2 of 2 File: USPT Nov 19, 2002

US-PAT-NO: 6482849
DOCUMENT-IDENTIFIER: US 6482849 B1

TITLE: Inhibitors of .alpha.4.beta.1 mediated cell adhesion

DATE-ISSUED: November 19, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lobl; Thomas J.	Foster City	CA		
Teegarden; Bradley R.	San Diego	CA		
Polinsky; Alexander	San Diego	CA		
Rishton; Gilbert M.	Thousand Oaks	CA		
Yamagishi; Masafumi	Hyogo-ken			JP
Tanis; Steven	Kalamazoo	MI		
Fisher; Jed F.	Three Rivers	MI		
Thomas; Edward W.	Kalamazoo	MI		
Chrusciel; Robert A.	Portage	MI		

US-CL-CURRENT: 514/430; 514/355, 514/400, 514/419, 514/448, 514/471, 514/478, 514/562, 514/563, 514/566, 546/316, 548/338.1, 548/495, 549/493, 549/69, 560/13, 560/27, 560/41, 562/430, 562/432

CLAIMS:

What is claimed is:

1. A compound of the formula (I): ##STR400##

wherein n is an integer of 1; R.sup.1 is a hydrogen atom or methyl group; R.sup.2 is a group of the formula: --CN, --COOH, --(C.sub.1-6 alkylene) OH, --CH.sub.2 O(C.sub.1-6 alkyl), --(C.sub.1-6 alkylene)COOH, --CH.sub.2 O(C.sub.1-6 alkylene)O(C.sub.1-6 alkyl), --CH.sub.2 O(C.sub.1-6 alkylene)COOH, --(C.sub.2-7 alkenylene) COOH, --CO(C.sub.1-6 alkylene)COOH, --CO(C.sub.2-7 alkenylene)COOH, --CO(C.sub.1-6 alkylene)O(C.sub.1-6 alkyl), --CO(C.sub.1-6 alkylene)CO(C.sub.1-6 alkyl), --CONH(C.sub.1-6 alkyl), --CONHO(C.sub.1-6 alkyl), --CONH(C.sub.1-6 alkylene)COOH, --CONH.sub.2, --CONH(C.sub.3-7 cycloalkyl), ##STR401## --CONHOCH.sub.2 Ph, --CONH(C.sub.1-6 alkylene)CN, --COO(C.sub.1-6 alkyl), --CH.sub.2 O(C.sub.1-6 alkylene)CONH.sub.2, --CONH(C.sub.1-6 alkylene)CONH.sub.2, --CONHOH, --NHCOOCH.sub.2 Ph, ##STR402## R.sup.3 is a hydrogen atom or a methyl group; X is a methylene group or a group of the formula: --CO--; R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl group; R.sup.5 is a group of the formula: --COOH or an ester or an amide thereof, --(C.sub.1-6 alkylene)COOH or an ester or an amide thereof, --(C.sub.1-7 alkylene)O(C.sub.1-6 alkyl), --(C.sub.1-7 alkylene)OH, --COO(C.sub.1-6 alkyl), --CONH(C.sub.1-6 alkyl), or --CONH.sub.2 ; R.sub.6 is a substituent of the formula: ##STR403## wherein, R.sup.7, which occurs one or more times and which may be the same or different in each occurrence, is --OH, --NO.sub.2, --NH.sub.2, --C.sub.1 -C.sub.5 alkyl, --F, --Cl, --Br, --I, --COOH, --COO(C.sub.1-6 alkyl), --O(C.sub.1 -C.sub.8 alkyl), --CONH(C.sub.1-6 alkylene)COOH, --OCH.sub.2 (C.sub.3 -C.sub.7 cycloalkyl) or a substituent of the formula ##STR404##

R.sup.8, which occurs one or more times and which may be the same or different in each occurrence, is --H, --OH, --NH.sub.2, --NO.sub.2, --C.sub.1 -C.sub.7 alkyl, --F, --Cl, --Br, --I, --CF.sub.3, phenyl, or --O(C.sub.1-6 alkyl); R.sup.9 is selected from a group of the formula: --H, --C.sub.1 -C.sub.5 alkyl, --C.sub.3 -C.sub.7 cycloalkyl, --(--C.sub.1 -C.sub.6 alkylene)aryl, aryl, where aryl is a substituent of the formula: ##STR405## R.sup.10, which occurs one or more times and which may be the same or different in each occurrence, is --H, --F, --Cl, --Br, --I, --NO.sub.2, --C.sub.1-6 alkyl or --O(C.sub.1-6 alkyl) with the proviso that R.sup.1 and R.sup.3 must be different and also with the proviso that when R.sup.2 or R.sup.6 is a moiety of the formula --COOH or contains a moiety of the formula --COOH, then a pharmaceutically acceptable ester or a pharmaceutically acceptable amide thereof are included, and also with the proviso that when R.sup.7 is the formula ##STR406## R.sup.9 is other than hydrogen; or

a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, which is a compound of the formula (I-1): ##STR407##

wherein n, R.sup.1 through R.sup.6 and X are as defined above.

3. The compound according to claim 1, which is a compound of the formula (I-2): ##STR408##

wherein n, R.sup.1 through R.sup.4, R.sup.6 and X are as defined above and R.sup.5 is a group of the formula: --COOH, --(C.sub.1-6 alkylene)COOH, --(C.sub.1-7 alkylene)O(C.sub.1-6 alkyl), -(C.sub.1-7 alkylene)OH, --COO(C.sub.1-6 alkyl), --CONH(C.sub.1-6 alkyl), or --CONH.sub.2.

4. The compound according to claim 1, wherein R.sup.6 ##STR409##

wherein Y is a hydrogen atom or a chlorine atom.

5. The compound according to claim 1, wherein R.sup.2 is a group of the formula: --COOH or an ester or an amide thereof, --CONHCH.sub.2 COOH, --CONHOCH.sub.2 Ph or --CONHCH.sub.2 CONH.sub.2.

6. The compound according to claim 1, wherein R.sup.1 is --CH.sub.3, R.sup.2 is --COOH, --CONHCH.sub.2 COOH, CONHOCH.sub.2 Ph or --CONHCH.sub.2 CONH.sub.2, R.sup.3 is hydrogen, X is --CO--, R.sup.4 is hydrogen, R.sup.5 is --COOH, n is 1,and R.sup.6 is ##STR410## wherein R.sup.7 is ##STR411## wherein R.sup.8 is substituted 2 or 3 times and is --Cl.

7. The compound according to claim 1, wherein said compound is selected from the group consisting of Examples 10, 12, 13, 14, 16, 46, 53, 54, 61, 62, 63, 65, 75, 79, 81, 83, 85, 87, 89, 91, 92, 93, 95, 96, 97, 100, 102, 103, 104, 105, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, 126, 128, 132, 134, 136, 141, 142, 144, 148, 150, 152, 153, 155, 161, 166, 170, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 211, 214, 216, 217, 219, 220, 221, 222, 223, 231, 232 and 236.

8. The compound according to claim 7, wherein said compound is selected from the group consisting of Examples 10, 12, 46, 53, 54, 61, 63, 65, 75, 81, 83, 87, 89, 91, 92, 93, 95, 97, 100, 102, 103, 104, 105, 106, 108, 110, 112, 114, 116, 118, 120, 121, 122, 124, 126, 128, 132, 134, 141, 142, 144, 148, 150, 152, 153, 161, 166, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 211, 214, 216, 217, 219, 220, 222, 223, 231, 232 and 236.

9. The compound according to claim 8, wherein said compound is selected from the group consisting of Examples 12, 54, 65, 81, 83, 87, 92, 93, 97, 100, 102, 103, 104, 106, 108, 110, 112, 114, 116, 148, 152, 166, 180, 181, 182, 183, 184, 211, 214, 216, 217, 219, 222, 223, 231, 232 and 236.

10. The compound according to claim 1, wherein said compound is selected from

the group consisting of Examples 2, 10, 12, 13, 53, 54, 61, 63, 65, 75, 81, 83, 85, 86, 87, 89, 91, 92, 93, 95, 97, 100, 102, 103, 104, 105, 106, 108, 110, 112, 113, 114, 116, 118, 120, 121, 124, 126, 128, 132, 136, 137, 141, 142, 143, 144, 146, 148, 150, 152, 153, 155, 163, 166, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 211, 214, 216, 217, 219, 220, 221, 222, 223, 231, 232 and 236.

11. The compound according to claim 10, wherein said compound is selected from the group consisting of Examples 10, 12, 54, 61, 63, 65, 75, 81, 83, 85, 87, 89, 91, 92, 93, 95, 97, 100, 102, 103, 104, 105, 106, 108, 110, 112, 114, 116, 120, 124, 126, 128, 132, 137, 142, 144, 146, 148, 152, 153, 166, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 211, 214, 216, 217, 219, 220, 222, 223, 232 and 236.

12. The compound according to claim 11, wherein said compound is selected from the group consisting of Examples 12, 54, 63, 83, 87, 91, 92, 93, 97, 100, 102, 103, 104, 106, 108, 110, 112, 116, 152, 166, 179, 180, 181, 182, 183, 184, 211, 214, 216, 217, 219, 223 and 232.

13. The compound according to claim 1, wherein said compound is selected from the group consisting of
(1S-cis)-N-[(3-Carboxy-2,2,3-trimethylcyclopentyl)carbonyl]-O-[(2,6-dichlorophenyl)methyl]-L-tyrosine,
(1S-cis)-N-[(3-Carboxy-2,2,3-trimethylcyclopentyl)carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine,
(1S-cis)-N-[(3-Carboxy-2,2,3-trimethylcyclopentyl)carbonyl]-O-[(2,6-dichlorophenyl)methyl]-3-nitro-L-tyrosine,
(1S-cis)-N-[(3-Carboxy-2,2,3-trimethylcyclopentyl)carbonyl]-4-[[(2,4,6-trichlorophenyl)carbonyl]-amino]-L-phenylalanine,
(1S-cis)-N-[[3-[[(2-Amino-2-oxoethyl)-amino]carbonyl]-2,2,3-trimethylcyclopentyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine,
(1S-cis)-N-[[3-[[(Carboxymethyl)amino]carbonyl]-2,2,3-trimethylcyclopentyl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine, and
(1S-cis)-N-[(3-Cyano-2,2,3-trimethylcyclopentyl)carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine.

14. A pharmaceutical composition comprising: a therapeutically effective amount of the compound as set forth in claim 1; and a pharmaceutically acceptable carrier or diluent.

15. A method for treating or preventing .alpha..sub.4.beta..sub.1 adhesion mediated conditions in a human which comprises administering to a patient an effective amount of the compound according to claim 1.

16. A method according to claim 15, wherein said condition is selected from the group consisting of rheumatoid arthritis, asthma, allergy conditions, allograft rejection, psoriasis, eczema, contact dermatitis and other skin inflammatory diseases, inflammatory and immunoinflammatory conditions including ophthalmic inflammatory conditions, inflammatory bowel diseases, atherosclerosis, and ulcerative colitis.

17. The compound according to claim 1, which is a compound as follows:
##STR412##

WEST

End of Result Set

☐ Generate Collection Print

L2: Entry 2 of 2 File: USPT Nov 19, 2002

DOCUMENT-IDENTIFIER: US 6482849 B1
TITLE: Inhibitors of .alpha.4.beta.1 mediated cell adhesion

Detailed Description Text (575):
VLA-4, a member of the .beta..sub.1 integrin family of adhesion molecules, is thought to play a critical role in several types of inflammatory disease processes by promoting leukocyte adhesion to vascular cell adhesion molecule (VCAM-1) and the CS-1 domain of fibronectin in extracellular tissue matrix (Elices M J, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler M, Lobb R R. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4-fibronectin binding site. Cell; 60: 577-584, 1990, Humphries M J, Akiyama S K, Komoriya A, Olden K, Yamada K M. Identification of an alternatively-spliced site in human plasma fibronectin that mediates cell type-specific adhesion. J Cell Biol; 103: 2637-2647, 1986, Wayner E A, Garcia-Pardo A, Humphries M J, McDonald J A, Carter W G. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol; 109: 1321-1330, 1989, Guan J-L, Hynes R O. Lymphoid cells recognize an alternatively-spliced segment of fibronectin via the integrin .alpha..sub.1.beta..sub.1. Cell; 60: 53-61, 1990). Of the cell types expressing VLA-4, the major emphasis has been on eosinophils, lymphocytes, and monocytes. Validation of the role of VLA-4 has relied predominantly on the use of anti-VLA-4 antibodies which have been shown to suppress delayed-type hypersensitivity responses (Issekutz T B. Dual inhibition of VLA-4 and LFA-1 maximally inhibits cutaneous delayed-type hypersensitivity-induced inflammation. Am J Pathol; 143: 1286-1293, 1993, Scheynius A, Camp R L, Pure E. Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. J Immunol; 150: 655-663, 1993, Ferguson T A, Kupper T S. Antigen-independent processes in antigen-specific immunity. J Immunol; 150: 1172-1182, 1993, Chisholm P L, Williams C A, Lobb R R. Monoclonal antibodies to the integrin .alpha.-4 subunit inhibit the murine contact hypersensitivity response. Eur J Immunol; 23: 682-688, 1993, Elices M J, Tamraz S, Tollefson V, Vollger L W. The integrin VLA-4 mediates leukocyte recruitment to skin inflammatory sites in vivo. Clin Exp Rheumatol; 11 (Suppl 8) S77-80), 1993, experimental allergic encephalomyelitis (Yednock T A, Cannon C, Fritz L C, Sanchez-Madrid F, Steinman L M, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against .alpha..sub.4.beta..sub.1 integrin. Nature; 356: 63-66, 1992, Canella B, Raine C S. The VCAM-1/VLA-4 pathway is involved in chronic lesion expression in multiple sclerosis (MS). J Neuropathol Exp Neurol; 52: 311, 1993), HIV-induced encephalitis (Sasseville V G, Newman W, Brodie S J, Hesterberg P, Pauley D, Ringler D J. Monocyte adhesion to endothelium in simian immunodeficiency virus-induced AIDS encephalitis is mediated by vascular cell adhesion molecule-1/.alpha..sub.4.beta..sub.1 integrin reactions. Am J Pathol; 144: 27-40, 1994), pulmonary inflammation and airway hyperreactvity in asthma (Abraham W M, Sielczak M W, Ahmed A, Cortes A, Lauredo I T, Kim J. Pepinsky, B, et al. .alpha..sub.4 -integrins mediate antigen-induced late bronchial responses and prolonged airway hyerresponsiveness in sheep. J Clin Invest; 93: 776-787, 1994, Pretolani M, Ruffie C, Roberto LapaeSilva J, Joseph D, Lobb R R, Vargaftig B B. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea-piq airways. J Exp Med; 180: 795-805, 1994), experimental models of autoimmune-mediated diabetes (Yang X-D, Karin N, Tisch R. Steinman L, McDevitt H O. Inhibition of insulitis and prevention of

diabetes in non-obese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. Proc Natl Acad Sci USA; 90: 10494-10498, 1993, Burkly L C, Jakubowski A, Hattori M. Protection against adoptive transfer of autoimmune diabetes medicated through very late antigen-4 integrin. Diabetes; 43: 529-534, 1994), and experimental colitis (Podolsky D K, Lobb R, King N, Benjamin C D, Pepinsky B, Sehgal P, et al. Attentuation of colitis in the cotton-top Tamarin by anti-.alpha.4 integrin monoclonal antibody. J Clin Invest; 92: 372-380, 1993). Since eosinophils represent a major component of the inflammatory cell influx in asthmatic lung tissue we developed a simple acute inflammatory model of VLA-4 integrin-dependent eosinophil infiltration which could be used to identify VLA-4 antagonists; such compounds would be of potential value in the treatment of asthma as well as other diseases in which VLA-4 played a role.

WEST

Generate Collection Print

L2: Entry 1 of 2 File: PGPB Nov 14, 2002

DOCUMENT-IDENTIFIER: US 20020168370 A1
TITLE: Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders

Detail Description Paragraph (349):
[0411] Tyor et al. (1993) A model of human immunodeficiency virus encephalitis in scid mice, Proc Natl Acad Sci USA 90:8658-62, provides an animal model of HIV-associated dementia complex to aid in development of treatments therefor. Mice with severe combined immunodeficiency (scid mice), which accept xenografts without rejection, were intracerebrally inoculated with human peripheral blood mononuclear cells and HIV. One to 4 weeks after inoculation, the brains of these mice contained human macrophages (some of which were HIV p24 antigen positive), occasional multinucleated cells, and striking gliosis by immunocytochemical staining. Human macrophages also were frequently positive for tumor necrosis factor type alpha and occasionally for interleukin 1 and VLA-4. Cultures of these brains for HIV were positive. Generally, human macrophages were not present in the brains of control mice, nor was significant gliosis, and HIV was not recovered from mice that received HIV only intracerebrally. Pathologically, this model of HIV encephalitis in scid mice resembles HIV encephalitis in humans and the data suggest that the activation of macrophages by infection with HIV results in their accumulation and persistence in brain and in the development of gliosis. This model of HIV encephalitis provides insights into the pathogenesis and treatment of this disorder.

Generate Collection | Print

Search Results - Record(s) 1 through 10 of 41 returned.

☐ 1. 20030039957 . 27 Nov 01. 27 Feb 03. Functional protein expression for rapid cell-free phenotyping. McCarthy, Laurence, et al. 435/5; 435/6 435/7.1 435/7.32 C12Q001/70 C12Q001/68 G01N033/53 G01N033/554 G01N033/569.

☐ 2. 20030027850 . 07 May 02. 06 Feb 03. Compounds which inhibit leukocyte adhesion mediated by VLA-4. Ashwell, Susan, et al. 514/372; 514/222.2 544/1 548/214 C07D417/02 C07D275/02.

☐ 3. 20030027771 . 07 May 02. 06 Feb 03. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4. Dressen, Darren B., et al. 514/19; 540/529 546/216 546/300 548/541 A61K038/05 C07K005/06 C07D211/40 C07D223/10.

☐ 4. 20030018004 . 22 Mar 02. 23 Jan 03. Vector. Kingsman, Susan Mary, et al. 514/44; 435/320.1 435/455 A61K048/00 C12N015/85.

☐ 5. 20030017993 . 16 Nov 01. 23 Jan 03. Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4. Thorsett, Eugene D., et al. 514/19; 514/211.01 514/222.2 514/372 514/562 540/544 544/3 548/214 562/430 A61K038/05 A61K031/554 A61K031/54 A61K031/195 A61K031/425.

☐ 6. 20030008398 . 14 Jun 02. 09 Jan 03. Self-enhancing, pharmacologically controllable expression systems. Mueller, Rolf, et al. 435/455; 435/320.1 536/23.2 C12N015/85 C07H021/04.

☐ 7. 20020197679 . 13 Mar 02. 26 Dec 02. Novel nucleic acids and polypeptides. Tang, Y. Tom, et al. 435/69.1; 435/183 435/320.1 435/325 530/350 536/23.2 C12P021/02 C12N005/06 C07H021/04 C12N009/00 C07K014/435.

☐ 8. 20020193312 . 15 Nov 01. 19 Dec 02. Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4. Thorsett, Eugene D., et al. 514/19; 514/211.01 514/222.2 514/372 514/562 540/544 544/3 548/214 562/430 A61K038/05 A61K031/554 A61K031/54 A61K031/425 C07D281/02 C07D275/02 C07D279/02.

☐ 9. 20020177551 . 30 May 01. 28 Nov 02. Compositions and methods for treatment of neoplastic disease. Terman, David S.. 514/12; 435/325 530/350 A61K038/17 C12N005/06 C07K014/705.

☐ 10. 20020169159 . 11 Dec 01. 14 Nov 02. CXCR3 antagonists. Medina, Julio C., et al. 514/227.5; 514/227.8 514/231.2 514/231.5 514/252.12 514/252.13 514/316 514/326 514/331 514/365 514/374 514/385 544/107 544/162 544/359 544/59 544/60 546/207 546/209 A61K031/541 A61K031/5377 A61K031/496 A61K031/454 C07D413/02 C07D417/02 C07D43/02 C07D41/02.

Generate Collection | Print

Generate Collection | Print

Search Results - Record(s) 11 through 20 of 41 returned.

☐ 11. 20020168370 . 22 Feb 01. 14 Nov 02. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders. McDonald, John R., et al. 424/178.1; 435/320.1 435/325 435/69.1 514/12 530/389.1 536/23.53 A61K039/395 C07H021/04 C12P021/02 C12N005/06 C07K016/46.

☐ 12. 20020098166 . 21 Jul 98. 25 Jul 02. GENETICALLY MODIFIED CELLS AND THEIR USE IN THE PROPHYLAXIS OR THERAPY OF DISORDERS. HAVEMANN, KLAUS, et al. 424/93.1; 435/325 A61K048/00 C12N005/06.

☐ 13. 20020058664 . 20 Jul 01. 16 May 02. Beta-amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4. Konradi, Andrei W., et al. 514/252.01; 514/252.05 514/255.05 514/256 514/272 544/238 544/324 544/405 C07D45/02 C07D43/02 A61K031/497 A61K031/501 A61K031/506.

☐ 14. 20020052470 . 20 Jul 01. 02 May 02. Alpha amino acid derivatives--inhibitors of leukocyte adhesion mediated by VLA-4. Konradi, Andrei W., et al. 530/331; 540/531 546/207 546/221 C07K005/08 C07D41/02.

☐ 15. 20020052375 . 19 Jul 01. 02 May 02. 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4. Konradi, Andrei W., et al. 514/252.01; 514/217.03 514/255.05 514/256 514/317 514/336 514/397 514/422 A61K031/55 A61K031/506 A61K031/501 A61K031/497 A61K031/4523 A61K031/4436 A61K031/4178.

☐ 16. 20020052308 . 10 Aug 01. 02 May 02. Nucleic acids, proteins and antibodies. Rosen, Craig A., et al. 514/1; 435/183 435/320.1 435/325 435/6 435/69.1 435/7.1 530/350 536/23.1 A61K031/00 C12Q001/68 G01N033/53 C07H021/04 C12N009/00 C07K014/435 C12N005/06.

☐ 17. 20020039745 . 31 Jul 98. 04 Apr 02. ANTI-INFLAMMATORY COMPOSITIONS AND METHOD. YEDNOCK, THEODORE A., et al. 435/7.1; 514/19 548/535 562/445 C07D207/00 C07C229/00 C07C317/00 C07C315/00 C07C311/00 C07C309/00 C07C307/00 C07C303/00 G01N033/53 A61K038/00.

☐ 18. 6525026 . 16 Nov 01; 25 Feb 03. Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4. Thorsett; Eugene D., et al. 514/19; 514/183 548/100 562/445. C07K005/06.

☐ 19. 6503713 . 04 Oct 00; 07 Jan 03. Methods for identifying RNA binding compounds. Rana; Tariq M. 435/6; 435/5 435/7.1 435/7.2 514/44 530/300 536/22.1 536/23.1 536/24.3. C12Q001/68 C07H019/00 C07H021/00 A01N043/04.

☐ 20. 6495346 . 12 Jan 00; 17 Dec 02. Complex-forming proteins. Jerome; Valerie, et al. 435/69.7; 424/85.1 424/85.2 435/69.5 435/69.52 530/351 536/23.4 536/23.5 536/23.51. C12N015/62 A61K038/20 C07K014/54.

Generate Collection | Print

Generate Collection | Print

Search Results - Record(s) 21 through 30 of 41 returned.

☐ 21. 6492421 . 30 Jul 98; 10 Dec 02. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4. Thorsett; Eugene D., et al. 514/562; 514/217.08 514/227.8 514/254.01 514/307 514/363 514/365 514/400 514/424 514/542 540/602 544/363 544/372 544/58.2 544/58.4 546/148 546/208 546/209 548/130 548/204 548/338.1 548/375.1 548/542 560/13 562/430. A61K031/19 C07C311/00.

☐ 22. 6492372 . 21 Jan 00; 10 Dec 02. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. Konradi; Andrei W., et al. 514/252.18; 514/183 514/256 514/275 544/328 544/329 544/330 544/332. A61K031/33 A61K031/505 A61K031/495 C07D239/02.

☐ 23. 6489300 . 31 Jul 98; 03 Dec 02. Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4. Thorsett; Eugene D., et al. 514/19; 548/535. C07K005/078.

☐ 24. 6482849 . 23 Jun 98; 19 Nov 02. Inhibitors of .alpha.4.beta.1 mediated cell adhesion. Lobl; Thomas J., et al. 514/430; 514/355 514/400 514/419 514/448 514/471 514/478 514/562 514/563 514/566 546/316 548/338.1 548/495 549/493 549/69 560/13 560/27 560/41 562/430 562/432. A61K031/27 A61K031/34 A61K031/195 A61K031/215.

☐ 25. 6482618 . 04 Apr 02; 19 Nov 02. Self-enhancing, pharmacologically controllable expression systems. Mueller; Rolf, et al. 435/91.41; 435/320.1 435/325 536/23.4 536/24.1. C12N015/66.

☐ 26. 6479492 . 21 Jan 00; 12 Nov 02. Compounds which inhibit leukocyte adhesion mediated by VLA-4. Konradi; Andrei W., et al. 514/241; 514/245 544/180 544/194 544/204 544/217 544/220. A61K031/53 C07D251/00 C07D251/48 C07D251/49.

☐ 27. 6465513 . 21 Jan 00; 15 Oct 02. Multicyclic compounds which inhibit leukocyte adhesion mediated by VLA-4. Grant; Francine S., et al. 514/529; 514/18 514/19 514/255.01 562/507. A01N037/00 C07C229/00.

☐ 28. 6436904 . 21 Jan 00; 20 Aug 02. Compounds which inhibit leukocyte adhesion mediated by VLA-4. Ashwell; Susan, et al. 514/19; 546/208 546/210 548/253 548/542. A61K038/05 C07K005/06.

☐ 29. 6423688 . 31 Jul 98; 23 Jul 02. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4. Thorsett; Eugene D., et al. 514/19; 514/18 530/331 548/535. C07K005/078.

☐ 30. 6410781 . 28 Feb 00; 25 Jun 02. .alpha.-aminoacetic acid derivatives-.alpha.4.beta.7 receptor antagonists. Konradi; Andrei W., et al. 560/133; 544/59 546/333 560/132. C07C271/44 A61K031/27.

Generate Collection | Print

Generate Collection | Print

Search Results - Record(s) 41 through 41 of 41 returned.

☐ 41. 5596090 . 12 Oct 93; 21 Jan 97. Antisense oligonucleotides directed against human VCAM-1 RNA. Hoke; Glenn D., et al. 536/24.5; 435/6 536/23.1 536/24.1 536/24.3 536/24.31. C07H021/04 A61K031/70.

Generate Collection | Print

Term	Documents
ENCEPHALITIS.USPT,PGPB.	3762
ENCEPHALITI.USPT,PGPB.	1
VIRAL.USPT,PGPB.	47119
VIRALS.USPT,PGPB.	337
ALPHA4.USPT,PGPB.	148
ALPHA4S	0
VLA-4.USPT,PGPB.	599
VLA-4S	0
VIRUS$	0
VIRUS.USPT,PGPB.	53937
VIRUSABILITY.USPT,PGPB.	2
((ENCEPHALITIS) SAME (VIRAL OR VIRUS$) AND (ALPHA4 OR 'VLA-4')).USPT,PGPB.	41

There are more results than shown above. Click here to view the entire set.

Previous Page Next Page

WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences | Cases

Search Results -

Term	Documents
ENCEPHALITIS.USPT,PGPB.	3762
ENCEPHALITI.USPT,PGPB.	1
VIRAL.USPT,PGPB.	47119
VIRALS.USPT,PGPB.	337
ALPHA4.USPT,PGPB.	148
ALPHA4S	0
VLA-4.USPT,PGPB.	599
VLA-4S	0
VIRUS$	0
VIRUS.USPT,PGPB.	53937
VIRUSABILITY.USPT,PGPB.	2
((ENCEPHALITIS) SAME (VIRAL OR VIRUS$) SAME(ALPHA4 OR 'VLA-4')).USPT,PGPB.	2

There are more results than shown above. Click here to view the entire set.

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L2

Refine Search

Recall Text | Clear

Search History

DATE: Friday, March 07, 2003 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB; PLUR=YES; OP=ADJ			
L2	(encephalitis) same (viral or virus$) same(alpha4 or 'vla-4')	2	L2
L1	(encephalitis) same (viral or virus$) and (alpha4 or 'vla-4')	41	L1

END OF SEARCH HISTORY

Term	Documents
ENCEPHALITIS.USPT,PGPB.	3762
ENCEPHALITI.USPT,PGPB.	1
VIRAL.USPT,PGPB.	47119
VIRALS.USPT,PGPB.	337
ALPHA4.USPT,PGPB.	148
ALPHA4S	0
VLA-4.USPT,PGPB.	599
VLA-4S	0
VIRUS$	0
VIRUS.USPT,PGPB.	53937
VIRUSABILITY.USPT,PGPB.	2
((ENCEPHALITIS) SAME (VIRAL OR VIRUS$) AND (ALPHA4 OR 'VLA-4')).USPT,PGPB.	41

There are more results than shown above. Click here to view the entire set.

Previous Page Next Page

Term	Documents
ENCEPHALITIS.USPT,PGPB.	3762
ENCEPHALITI.USPT,PGPB.	1
VIRAL.USPT,PGPB.	47119
VIRALS.USPT,PGPB.	337
ALPHA4.USPT,PGPB.	148
ALPHA4S	0
VLA-4.USPT,PGPB.	599
VLA-4S	0
VIRUS$	0
VIRUS.USPT,PGPB.	53937
VIRUSABILITY.USPT,PGPB.	2
((ENCEPHALITIS) SAME (VIRAL OR VIRUS$) AND (ALPHA4 OR 'VLA-4')).USPT,PGPB.	41

There are more results than shown above. Click here to view the entire set.

Previous Page Next Page

Term	Documents
ENCEPHALITIS.USPT,PGPB.	3762
ENCEPHALITI.USPT,PGPB.	1
VIRAL.USPT,PGPB.	47119
VIRALS.USPT,PGPB.	337
ALPHA4.USPT,PGPB.	148
ALPHA4S	0
VLA-4.USPT,PGPB.	599
VLA-4S	0
VIRUS$	0
VIRUS.USPT,PGPB.	53937
VIRUSABILITY.USPT,PGPB.	2
((ENCEPHALITIS) SAME (VIRAL OR VIRUS$) AND (ALPHA4 OR 'VLA-4')).USPT,PGPB.	41

There are more results than shown above. Click here to view the entire set.

Previous Page Next Page